Sumary of Nafabeltan out, but push for homegrown COVID-19 drug continues:
- The competition to develop the country second COVID-19 treatment continues among South Korea major pharmaceutical companies after Chong Kun Dang Pharmaceutical recently dropped out…
- South Korea Ministry of Food and Drug Safety announced Wednesday that it has decided not to approve Chong Kun Dang Pharmaceutical candidate, Nafabeltan, based on a review by its advisory board of its efficacy and safety…
- Chong Kun Dang Pharmaceutical acute pancreatitis drug was one of two strong candidates to become the country No…
- 2 treatment for COVID-19, following Rekirona by Celltrion, which became the first commercially available therapy developed by a local firm in February…
- Now, the next in line is GC Pharma blood plasma-derived therapy, GC5131A, which is intended to treat more serious COVID-19 cases….